Vascular endothelial growth factor broadens lentivector distribution in the heart after neonatal injection

Journal of Cardiology

Volumn 54, Issue 2, 2009, Pages 245-254

  Sato, Takeya ^a,b   Ramsubir, Shobha ^c   Higuchi, Koji ^b   Yanagisawa, Teruyuki ^a   Medin, Jeffrey A ^b,c  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Gene expression; Gene based therapy; Immunologic techniques; Myocardium

Indexed keywords

LENTIVIRUS VECTOR; LUCIFERASE; MANNITOL; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; GENE EXPRESSION; GENE TRANSFER; GENETIC ENGINEERING; IMMUNOHISTOCHEMISTRY; MOUSE; NEWBORN; NONHUMAN; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANIMALS, NEWBORN; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; LENTIVIRUS; LUCIFERASES, FIREFLY; MICE; MICE, INBRED BALB C; MYOCARDIUM; STIMULATION, CHEMICAL; TRANSDUCTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70349244738     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jjcc.2009.05.010     Document Type: Article

References (36)

1. Higuchi K., Ayach B., Sato T., Chen M., Devine S.P., Rasaiah V.I., Dawood F., Yanagisawa T., Tei C., Takenaka T., Liu P.P., and Medin J.A. Direct injection of kit ligand-2 lentivirus improves cardiac repair and rescues mice post-myocardial infarction. Mol Ther 17 (2009) 262-268
2. Boink G.J., Verkerk A.O., van Amersfoorth S.C., Tasseron S.J., van der Rijt R., Bakker D., Linnenbank A.C., van der Meulen J., de Bakker J.M., Seppen J., and Tan H.L. Engineering physiologically controlled pacemaker cells with lentiviral HCN4 gene transfer. J Gene Med 10 (2008) 487-497
3. Hurttila H., Koponen J.K., Kansanen E., Jyrkkänen H.K., Kivelä A., Kylätie R., Ylä-Herttuala S., and Levonen A.L. Oxidative stress-inducible lentiviral vectors for gene therapy. Gene Ther 15 (2008) 1271-1279
4. Niwano K., Arai M., Koitabashi N., Watanabe A., Ikeda Y., Miyoshi H., and Kurabayashi M. Lentiviral vector-mediated SERCA2 gene transfer protects against heart failure and left ventricular remodeling after myocardial infarction in rats. Mol Ther 16 (2008) 1026-1032
5. Yoshimitsu M., Sato T., Tao K., Walia J.S., Rasaiah V.I., Sleep G.T., Murray G.J., Poeppl A.G., Underwood J., West L., Brady R.O., and Medin J.A. Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors. Proc Natl Acad Sci USA 101 (2004) 16909-16914
6. Brady R.O., Gal A.E., Bradley R.M., Martensson E., Warshaw A.L., and Laster L. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 276 (1967) 1163-1167
7. Frustaci A., Chimenti C., Ricci R., Natale L., Russo M.A., Pieroni M., Eng C.M., and Desnick R.J. Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N Engl J Med 345 (2001) 25-32
8. Sheth K.J., Roth D.A., and Adams M.B. Early renal failure in Fabry's disease. Am J Kidney Dis 2 (1983) 651-654
9. Nakao S., Takenaka T., Maeda M., Kodama C., Tanaka A., Tahara M., Yoshida A., Kuriyama M., Hayashibe H., Sakuraba H., and Tanaka H. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 333 (1995) 288-293
10. Eng C.M., Guffon N., Wilcox W.R., Germain D.P., Lee P., Waldek S., Caplan L., Linthorst G.E., Desnick R.J., and International Collaborative Fabry Disease Study Group. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med 345 (2001) 9-16
11. Schiffmann R., Kopp J.B., Austin III H.A., Sabnis S., Moore D.F., Weibel T., Balow J.E., and Brady R.O. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285 (2001) 2743-2749
12. Weidemann F., Breunig F., Beer M., Sandstede J., Turschner O., Voelker W., Ertl G., Knoll A., Wanner C., and Strotmann J.M. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 108 (2003) 1299-1301
13. Medin J.A., Tudor M., Simovitch R., Quirk J.M., Jacobson S., Murray G.J., and Brady R.O. Correction in trans for Fabry disease: expression, secretion and uptake of alpha-galactosidase A in patient-derived cells driven by a high-titer recombinant retroviral vector. Proc Natl Acad Sci USA 93 (1996) 7917-7922
14. Qin G., Takenaka T., Telsch K., Kelley L., Howard T., Levade T., Deans R., Howard B.H., Malech H.L., Brady R.O., and Medin J.A. Preselective gene therapy for Fabry disease. Proc Natl Acad Sci USA 98 (2001) 3428-3433
15. Takenaka T., Murray G.J., Qin G., Quirk J.M., Ohshima T., Qasba P., Clark K., Kulkarni A.B., Brady R.O., and Medin J.A. Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells. Proc Natl Acad Sci USA 97 (2000) 7515-7520
16. Yoshimitsu M., Higuchi K., Dawood F., Rasaiah V.I., Ayach B., Chen M., Liu P., and Medin J.A. Correction of cardiac abnormalities in fabry mice by direct intraventricular injection of a recombinant lentiviral vector that engineers expression of alpha-galactosidase A. Circ J 70 (2006) 1503-1508
17. Yoshimitsu M., Higuchi K., Ramsubir S., Nonaka T., Rasaiah V.I., Siatskas C., Liang S.B., Murray G.J., Brady R.O., and Medin J.A. Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem/progenitor cells. Gene Ther 14 (2007) 256-265
18. Bates D.O., Lodwick D., and Williams B. Vascular endothelial growth factor and microvascular permeability. Microcirculation 6 (1999) 83-96
19. Nagy J.A., Vasile E., Feng D., Sundberg C., Brown L.F., Detmar M.J., Lawitts J.A., Benjamin L., Tan X., Manseau E.J., Dvorak A.M., and Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med 196 (2002) 1497-1506
20. Proescholdt M.A., Heiss J.D., Walbridge S., Mühlhauser J., Capogrossi M.C., Oldfield E.H., and Merrill M.J. Vascular endothelial growth factor (VEGF) modulates vascular permeability and inflammation in rat brain. J Neuropathol Exp Neurol 58 (1999) 613-627
21. Qu H., Nagy J.A., Senger D.R., Dvorak H.F., and Dvorak A.M. Ultrastructural localization of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) to the abluminal plasma membrane and vesiculovacuolar organelles of tumor microvascular endothelium. J Histochem Cytochem 43 (1995) 381-389
22. Dvorak H.F., Brown L.F., Detmar M., and Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146 (1995) 1029-1039
23. Young P.P., Fantz C.R., and Sands M.S. VEGF disrupts the neonatal blood-brain barrier and increases life span after non-ablative BMT in a murine model of congenital neurodegeneration caused by a lysosomal enzyme deficiency. Exp Neurol 188 (2004) 104-114
24. Sarzotti M. Immunologic tolerance. Curr Opin Hematol 4 (1997) 48-52
25. Ponder K.P. Immunology of neonatal gene transfer. Curr Gene Ther 7 (2007) 403-410
26. Waddington S.N., Kennea N.L., Buckley S.M., Gregory L.G., Themis M., and Coutelle C. Fetal and neonatal gene therapy: benefits and pitfalls. Gene Ther 11 Suppl 1 (2004) S92-S97
27. Baekelandt V., Claeys A., Cherepanov P., De Clercq E., De Strooper B., Nuttin B., and Debyser Z. DNA-Dependent protein kinase is not required for efficient lentivirus integration. J Virol 74 (2000) 11278-11285
28. Boussif O., Lezoualc'h F., Zanta M.A., Mergny M.D., Scherman D., Demeneix B., and Behr J.P. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 92 (1995) 7297-7301
29. Sharp T.V., Wang H.W., Koumi A., Hollyman D., Endo Y., Ye H., Du M.Q., and Boshoff C. K15 protein of Kaposi's sarcoma-associated herpesvirus is latently expressed and binds to HAX-1, a protein with antiapoptotic function. J Virol 76 (2002) 802-816
30. Linhart A., Lubanda J.C., Palecek T., Bultas J., Karetova D., Ledvinova J., Elleder M., and Aschermann M. Cardiac manifestations in Fabry disease. J Inherit Metab Dis 24 Suppl 2 (2001) 75-83
31. Shah J.S., Hughes D.A., Sachdev B., Tome M., Ward D., Lee P., Mehta A.B., and Elliott P.M. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol 96 (2005) 842-846
32. Wilcken D.E. Overview of inherited metabolic disorders causing cardiovascular disease. J Inherit Metab Dis 26 (2003) 245-257
33. Bates D.O., and Harper S.J. Regulation of vascular permeability by vascular endothelial growth factors. Vascul Pharmacol 39 (2002) 225-237
34. Carbonaro D.A., Jin X., Petersen D., Wang X., Dorey F., Kil K.S., Aldrich M., Blackburn M.R., Kellems R.E., and Kohn D.B. In vivo transduction by intravenous injection of a lentiviral vector expressing human ADA into neonatal ADA gene knockout mice: a novel form of enzyme replacement therapy for ADA deficiency. Mol Ther 13 (2006) 1110-1120
35. Kobayashi H., Carbonaro D., Pepper K., Petersen D., Ge S., Jackson H., Shimada H., Moats R., and Kohn D.B. Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector. Mol Ther 11 (2005) 776-789
36. Torashima T., Koyama C., Iizuka A., Mitsumura K., Takayama K., Yanagi S., Oue M., Yamaguchi H., and Hirai H. Lentivector-mediated rescue from cerebellar ataxia in a mouse model of spinocerebellar ataxia. EMBO Rep 9 (2008) 393-399